Shilpa Medicare surges on getting initial authorization for Rivaroxaban Orodispersible Films
Shilpa Medicare is currently trading at Rs 839.65, up by 22.40 points or 2.74% from its previous closing of Rs 817.25 on the BSE.
The scrip opened at Rs 823.00 and has touched a high and low of Rs 858.10 and Rs 823.00 respectively. So far 7864 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1003.20 on 16-Jun-2025 and a 52-week low of Rs 530.50 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 858.10 and Rs 809.85 respectively. The current market cap of the company is Rs 8211.01 crore.
The promoters holding in the company stood at 44.23%, while Institutions and Non-Institutions held 18.64% and 37.13% respectively.
Shilpa Medicare has received the initial authorization from European Medicine Agency (EMA) for its Rivaroxaban 10 mg, 15 mg, and 20 mg Orodispersible Films. This application, submitted as a hybrid application via the EMA’s Centralized Procedure, is a generic version of the innovator product Xarelto, from Bayer AG, which is available as oral tablets. Shilpa’s product is bioequivalent to the reference product Xarelto and is the only Rivaroxaban in ODF form which can help in patient comfort, especially in geriatric patients.
Shilpa’s Rivaroxaban Orodispersible Films is an anticoagulant medicine (a medicine that prevents blood clotting). It is used to treat deep vein thrombosis and pulmonary embolism, and to prevent their recurrence in adults. It is also used to prevent atherothrombotic events (such as heart attack, stroke or death from heart disease) in adults. It works by inhibiting a highly selective, direct factor Xa. The total Europe market for oral Rivaroxaban formulations is about $2.5 billion.
This approval has come from the Company’s finished dosage form manufacturing facility, Shilpa Medicare, Unit VI, located at Dabaspet, Bengaluru, Karnataka. The facility is currently approved by U.S. Food and Drug Administration (USFDA), Europe and MHRA UK. This is the third approval of a prescription oral mouth dissolving film product in the European markets from this facility. The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving Films and Transdermal Patches.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
